A Double Blind, Randomised, Placebo-Controlled, Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single, Ascending, Oral Doses of AZD2551 in Healthy Male Subjects.

Trial Profile

A Double Blind, Randomised, Placebo-Controlled, Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single, Ascending, Oral Doses of AZD2551 in Healthy Male Subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2010

At a glance

  • Drugs AZD 2551 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 02 Dec 2010 Planned end date changed from 1 Jun 2009 to 1 May 2009 as reported by ClinicalTrials.gov.
    • 11 Dec 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top